HLA - A B C DR DQ FOR HSCT

The HLA A B C DR DQ test analyzes the human leukocyte antigen (HLA) markers important for hematopoietic stem cell transplantation (HSCT). Matching these HLA loci between donor and recipient reduces the risk of transplant rejection. It is crucial for selecting suitable donors for stem cell transplants.

Also known asHla A B C Dr Dq For Hsct Hla A B C Dr Dq For Hsct

Available via

Home Collection, Lab Visit

Contains

6 parameters

Earliest reports in

3 Working Days

Test details

HLA - A B C DR DQ FOR HSCT Test in Mangaluru Overview

Preparations

No special preparations needed

Test included
HLA - A B C DR DQ FOR HSCT includes 6 parameters

  • Hla-a
  • Hla-b
  • Hla-c
  • Hla-dr
  • Hla-dq (alpha)
  • Hla-dq (beta)
Frequently Asked Questions

 The HLA A-B-C DR DQ test is a comprehensive human leukocyte antigen (HLA) typing test that identifies specific genetic markers located on chromosomes that play a key role in immune function. This test examines multiple loci—HLA-A, HLA-B, HLA-C, HLA-DR, and HLA-DQ—which are essential for determining compatibility between a donor and a recipient for hematopoietic stem cell transplantation (HSCT), also known as bone marrow transplantation. A close match at these loci reduces the risk of graft rejection and severe complications like graft-versus-host disease (GVHD), improving the chances of a successful transplant.

This test is typically performed on a blood sample, though cheek swabs or buccal cells can also be used in certain cases. The sample is analyzed using advanced molecular techniques such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) to precisely identify the HLA alleles present in both the donor and the recipient. High-resolution typing ensures accurate and detailed results, which are necessary when selecting donors for HSCT.

 A high match between the donor and recipient at the HLA A-B-C DR DQ loci significantly increases the likelihood that the transplanted stem cells will engraft successfully and begin producing healthy blood cells. It also minimizes the risk of complications such as GVHD, where the donor’s immune cells attack the recipient’s tissues. In general, a 10/10 or 12/12 allele match is considered ideal and is associated with the best post-transplant outcomes. In cases where a perfect match is not available, partially matched or haploidentical transplants may be considered with additional medical management.

This test is performed on both the patient in need of a transplant and potential stem cell donors, including family members and unrelated registered donors. It is a critical first step in the donor selection process for individuals with hematologic malignancies such as leukemia, lymphoma, and aplastic anemia, as well as some inherited metabolic or immunodeficiency disorders. The test results help determine the most suitable donor among available options.

While HLA matching is one of the most crucial aspects in selecting a donor, it is not the only factor. Other considerations include donor age, health status, cytomegalovirus (CMV) status, blood type compatibility, and the presence of any known genetic mutations or infections. Nonetheless, a strong HLA match forms the foundation of successful hematopoietic stem cell transplantation and significantly influences the patient’s prognosis and recovery.

Test code

4852B

Specimen vol. and vacutainer information
SpecimenVacutainerVolume
Edta Whole BloodLavender Vacutainer10 ML

Specimen stability information

Edta Whole Blood, Edta Whole Blood

Specimen rejection criteria

Test run frequency

'

Turn around time

3 Working Days

Performing locations

Department

  • Hla Serology

CPT and Loinc codes

HLA - A B C DR DQ FOR HSCT

27000